PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma
Status:
Completed
Trial end date:
2018-10-25
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate pharmacodynamic changes of Nivolumab and Nivolumab
in combination with Ipilimumab treatment on the biomarkers measured in the peripheral blood
and tumor tissues of subjects with advanced melanoma (unresectable or advanced)